A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV

  • STATUS
    Recruiting
  • End date
    Nov 10, 2023
  • participants needed
    60
  • sponsor
    WinSanTor, Inc
Updated on 9 June 2022

Summary

This is a two-part study of the safety, tolerability, and efficacy of topically administered WST-057 for 16 weeks in subjects with HIV with sensory polyneuropathy.

Description

Phase A: Is an open-labeled feasibility investigation of the safety, tolerability, and limited efficacy in 14 subjects with HIV-associated distal sensory polyneuropathy (HIV-DSP) after topical daily dosing of WST-057 (4% pirenzepine free base monohydrate). Subjects will be stratified based on their baseline scores for pain/discomfort using the VAS. Subjects will attend visits at screening; Day 0 (baseline); Weeks 4, 8, and 16; and follow-up (Week 18).

Phase B: Is a randomized outpatient, double-blind, placebo-controlled, single-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 for 16 weeks in subjects with HIV-associated distal sensory polyneuropathy (HIV-DSP). Stratification of subjects based on baseline pain will be included based on the results of Part A.

Subjects will attend visits at screening; Day 0 (baseline); Weeks 4, 8, and 16; and follow-up (Week 18). Approximately 60 subjects with HIV-DSP will be randomized to 1 of 2 treatment groups in a 3:2 ratio: WST-057 (4 mL) (n = 36 subjects) versus placebo control 4 mL (n = 24 subjects); with the assumption that a total of 50 subjects will complete the study.

This study is designed with 4 periods in both study phases: screening, baseline/day 0, outpatient treatment, and safety follow-up.

Details
Condition HIV Associated Polyneuropathy
Treatment WST-057
Clinical Study IdentifierNCT05005078
SponsorWinSanTor, Inc
Last Modified on9 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients are eligible for the study if all the following criteria are met
HIV infection documented by serologic testing at screening; virally suppressed on ART
Male and female patients in the age range of 18 to 80 years (inclusive)
Diagnosis of HIV-DSP determined by a neurological exam performed by qualified personnel and defined as one or more clinical signs (symmetrical, diminished distal vibration or dull/sharp sensation in feet or reduced ankle reflexes using HNRC CH40)
Prior week VAS for average pain/discomfort (altered sensation) and/or altered sensations on lower extremities > 20 mm and < 80mm (0 mm = no pain-100 mm = very severe pain) at screening
Baseline IENF density <5%ile (ankle) based on age- and sex-adjusted Lauria norms
Provide written informed consent prior to entering the study or undergoing any study procedures
Females should be either not of childbearing potential as a result of surgery or menopause (1 year after onset), or of childbearing potential and must be practicing a highly effective medically acceptable method of contraception, including abstinence; hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device or intrauterine system; or vasectomy (partner), for at least 1 month before the screening visit and for 1 month after the end of the last dose of study drug. If access or use of a highly effective medically acceptable method of contraception is not achievable, then a combination of barrier methods (e.g., male condom, female condom, cervical cap, diaphragm, contraceptive sponge) is acceptable. Eligible female subjects must also have a negative serum beta-human chorionic gonadotropin at the screening visit
Males must use an acceptable form of contraception (e.g., male condom with diaphragm, male condom with cervical cap, or male condom in association with spermicide)
If diabetic, glycemic control has been optimized and has been stable for at least three months prior to randomization. Optimal glycemic control (by HgbA1C<7; at discretion of PI) refers to the best possible diabetic control that an individual patient can attain with usual standards of care, which usually takes more than two months to establish
Participating subjects must be reliable, willing, and able to cooperate with all study procedures, including the following
Return for study visits on the required dates
Be physically able to inspect calves, tops of ankles, and soles of feet for wounds, infections, or other anomalies, and be able to self-administer the investigational drug to calves and top surface of feet
Be able to accurately and reliably report symptoms (including treatment-emergent signs and symptoms)
Take study drug as required by protocol
If diabetic, be on stable antidiabetic treatment (> 2 months prior to screening) (oral
Be on stable nonpharmacological pain/uncomfortable sensation treatment for at least 4 weeks prior to screening and remain on this stable treatment throughout the study (unless otherwise directed by a physician). Nonpharmacologic pain treatment includes the following: relaxation/hypnosis, physical or occupational therapy, counseling, etc. Episodic or periodic treatments, such as monthly injections for treatment of pain (e.g., local anesthetics) or trans electrical nerve stimulation will not be permitted
or injectable antidiabetic therapy and/or lifestyle) that is not anticipated
Regular and stable use of pharmacological pain/uncomfortable sensation treatment (less than or equal to 30 mg morphine equivalent) for at least 8 weeks prior to screening
to change during the course of the study, except if medically required
General health status must be acceptable for participation in this 16-week clinical study, during screening per judgment of the Investigator. Any question regarding eligibility will be addressed with the medical monitor
Fluency (oral and written) in the language in which the standardized tests will be administered (English or Spanish)

Exclusion Criteria

Subjects who meet any of the following exclusion criteria will be excluded from
participating in the study
Individuals with the onset of Type 2 diabetes mellitus before HIV infection
Current intoxication (BAC > 0.08%) at the screening visit at the discretion of the
Uncontrolled or Insulin-dependent diabetes mellitus
investigator (breathalyzer analysis)
Proliferative retinopathy or maculopathy requiring acute treatment
Neuropathy due to exposure to current use/ chemotherapeutic agents or other
neurotoxins; at the discretion of the investigator
Requiring dialysis. Impaired liver function, defined as aspartate aminotransferase or
Clinically significant - confirmed by bladder ultrasound regardless of etiology
alanineaminotransferase > 3 times the upper limit of normal
Uncontrolled glaucoma
Presence of clinically significant peripheral or autonomic neuropathy that is clearly
of non HIV-DSP origin
Active and/or systemic infections with hepatitis C (as per investigator judgement
following serology results) or syphilis, or a history of severe infection during the
days prior to screening
Diagnosis and/or treatment of malignancy (except for basal cell or squamous cell skin
cancer, in-situ carcinoma of the cervix, or in-situ prostate cancer) within the past 5
years
Amputations of lower extremities or presence of foot ulcers
Clinically significant diagnosed gastric emptying abnormality (e.g., severe
gastroparesis)
A history of severe infection during the 30 days prior to screening
Major surgical procedure during the 90 days prior to screening
Other clinically significant, active (over the past 12 months) disease of the
gastrointestinal, pulmonary, neurological, genitourinary, endocrine, rheumatologic or
Failure or inability to perform screening or baseline assessments
hematological system that, in the opinion of the Investigator, would compromise the
subject's participation in the study, might confound the results of the study, or pose
additional risk in administering the study drug.unstable/untreated clinically
significant
New treatment with (< 2 months) antioxidant supplements, vitamins, or drugs known to
affect oxidative stress and such as Superoxide Dismutase, Alpha Lipoic Acid, Acetyl
L-Carnitine and Vitamin B12
Mental incapacity, unwillingness, or language barrier precluding adequate
understanding of or cooperation with the study
Women of childbearing potential who are pregnant, breast-feeding, or intend to become
pregnant. Women of childbearing potential must have a negative pregnancy test at
Screening and must agree to use adequate contraceptive methods during the study and
for 1 month after the last dose of study drug (see inclusion criterion 5)
History of allergy or sensitivity to M1 antagonists or anticholinergics in general or
any of the components of the investigational product formulations
Local (topical) anesthetics or analgesics including lidocaine, capsaicin, cannabinoid
(CBD) oil/products or compounded topical pharmaceutical agents
Uncontrolled treated/untreated hypertension (systolic blood pressure [BP] > 180 or
diastolic BP > 100 at screening)
Clinically significant active macrovascular disease, including myocardial infarction
or cerebrovascular event within the past 6 months
History of sensitive skin, as defined by a requirement to use soap and skin products
formulated for "sensitive skin," as determined by the Investigator
Currently taking M1 antagonists medicines to treat overactive bladder (anticholinergic
agents, such as Gelnique), or antispasmodics
Patients with any condition that could potentially interfere with the conduct of the
study or confound efficacy evaluations, including the following as specified in
numbers 26 through 32 below
Pain or neuropathy from another cause, as determined by the investigator (including
central pain, radiculopathy, painful arthritis, etc.)
Active skin or soft-tissue lesions in the dosing area (calves, ankles and tops of
feet) affected by neuropathy that are painful or could alter sensation
Exposure to an experimental drug, experimental biologic, or experimental medical
device within 3 months before screening
Any open wound(s) and/or sunburn(s) in the dosing area. Subjects who have a wound
and/or sunburn at screening that is anticipated to resolve before day -1 can be
enrolled
History of a serious skin disease (as determined by the Investigator), such as skin
cancer, psoriasis, stasis dermatitis or eczema
Receipt of a tattoo in the dosing area within 12 months of dosing
Known or untreated Lyme disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note